Law firm Stephenson Harwood LLP has advised e-therapeutics plc on a fundraise of £22.5 million.

Based in Oxford, UK, e-therapeutics aims to transform the drug discovery process by leveraging its computational power and biological expertise to accelerate the path to identifying and developing effective therapies. The company has developed a proprietary, disease-agnostic platform to produce valuable disease biological insights and potential drug candidates.

The all equity fundraise of £22.5 million comprises a placing with institutional investors, as well as direct subscriptions from individual investors and an offer to retail and other investors via the PrimaryBid platform. The raise, which is conditional on approval by shareholders at the company’s 2021 annual general meeting, follows a £12.4 million equity fundraise on which the team at Stephenson Harwood advised in July 2020.

Stephenson Harwood partner Anthony Clare advised e-therapeutics on the fundraise. The firm’s award-winning life sciences group advises clients from across the industry, including pharmaceutical, biotechnology, medical device and diagnostic developers, manufacturers, distributors and logistics companies, as well as investors, banks and financial institutions.